A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Katharina A MayerEva SchrezenmeierMatthias DieboldPhilip F HalloranMartina SchatzlSabine SchranzSusanne HaindlSilke KasbohmAlexander KainzFarsad EskandaryKonstantin DobererUptal D PatelJaideep S DudaniHeinz RegeleNicolas KozakowskiJohannes Philipp KlägerRainer BoxhammerKerstin AmannElisabeth Puchhammer-StöcklHannes VietzenJulia BeckEkkehard SchützAylin AkifovaChrista FirbasHouston N GilbertBilgin OsmanodjaFabian HalleckBernd JilmaKlemens BuddeGeorg A BöhmigPublished in: The New England journal of medicine (2024)
Felzartamab had acceptable safety and side-effect profiles in patients with antibody-mediated rejection. (Funded by MorphoSys and Human Immunology Biosciences; ClinicalTrials.gov number, NCT05021484; and EUDRACT number, 2021-000545-40.).